Appointment of Water Tower Research

AI SummaryClose X

Solvonis Therapeutics plc has appointed Water Tower Research LLC to enhance its understanding of the U.S. market, refine its corporate profile, and expand institutional investor reach, particularly as it advances its pipeline programs including SVN-002 for alcohol use disorder, SVN-015 for stimulant addiction, and SVN-114 for PTSD. This strategic move aims to address a perceived valuation gap with comparable U.S.-listed CNS peers and strengthen the company's equity story within the crucial U.S. capital markets.

Disclaimer*

UK 100

Latest directors dealings